Additionally, we show that a novel preclinical oncofetal CS-targeting drug conjugate effectively eliminates NSCLC cells in vitro and inhibits KRAS-mutated NSCLC xenograft tumor growth in vivo. The gene discussed is KRAS; the disease is neoplasm.